1. Antibacterial sequential growth factor delivery from alginate/gelatin methacryloyl microspheres for bone regeneration.
- Author
-
Dai M, Lin X, Hua P, Wang S, Sun X, Tang C, Zhang C, and Liu L
- Subjects
- Animals, Vascular Endothelial Growth Factor A pharmacology, Vascular Endothelial Growth Factor A chemistry, Vascular Endothelial Growth Factor A metabolism, Methacrylates chemistry, Methacrylates pharmacology, Mice, Hydrogels chemistry, Hydrogels pharmacology, Humans, Drug Liberation, Gelatin chemistry, Gelatin pharmacology, Microspheres, Alginates chemistry, Alginates pharmacology, Bone Regeneration drug effects, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Bone Morphogenetic Protein 2 pharmacology, Bone Morphogenetic Protein 2 chemistry
- Abstract
Autologous or allogeneic bone tissue grafts remain the mainstay of treatment for clinical bone defects. However, the risk of infection and donor scarcity in bone grafting pose challenges to the process. Therefore, the development of excellent biomaterial grafts is of great clinical importance for the repair of bone defects. In this study, we used gas-assisted microfluidics to construct double-cross-linked hydrogel microspheres with good biological function based on the ionic cross-linking of Cu
2+ with alginate and photo-cross-linking of gelatin methacryloylamide (GelMA) by loading vascular endothelial growth factor (VEGF) and His-tagged bone morphogenetic protein-2 (BMP2) (AGMP@VEGF&BMP2). The Cu2+ component in the microspheres showed good antibacterial and drug-release behavior, whereas VEGF and BMP2 effectively promoted angiogenesis and bone tissue repair. In in vitro and in vivo experiments, the dual cross-linked hydrogel microspheres showed good biological function and biocompatibility. These results demonstrate that AGMP@VEGF&BMP2 microspheres could be used as a bone defect graft substitute to promote effective healing of bone defects and may be applied to other tissue engineering studies., Competing Interests: Declaration of competing interest All authors disclosed no relevant relationships. This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. We have read and understood your journal's policies, and we believe that neither the manuscript nor the study violates any of these. There are no conflicts of interest to declare., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF